Program
faricimab
Also written as “Faricimab”, “Faricimab PFS Configuration” and “RO6867461”.
Its studies are mostly in Macular Edema · Macular Degeneration · Choroidal Neovascularization · Wet Macular Degeneration, led by Hoffmann-La Roche.
Furthest: phase 4, since Jan 25, 202217 company-led studies, 2 open or runningNext primary completion: Jan 26, 2027 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 172 open or running | phase 4since Jan 25, 2022 | Sep 3, 2013 | Jan 26, 2027phase 4 · NCT05224102 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 3, 2013First study: phase 1 study in Macular DegenerationFirst studyNCT01941082 · 24 enrolled · United States, United Kingdom
- Jun 12, 2015Phase 2 study in Choroidal NeovascularizationNCT02484690 · 273 enrolled · United States
- Mar 1, 2016Phase 2 study in Diabetic Macular EdemaNCT02699450 · 229 enrolled · United States
- Jan 31, 2017Phase 2 study in Choroidal NeovascularizationNCT03038880 · 76 enrolled · United States
- Aug 1, 20182 phase 3 studies in Diabetic Macular EdemaNCT03622593, NCT03622580
- Jan 29, 20192 phase 3 studies in Wet Macular DegenerationNCT03823300, NCT03823287
- Jun 12, 2020Phase 3 study in Diabetic Macular EdemaNCT04432831 · 1,479 enrolled · United States, Argentina, Australia and more
- Oct 19, 2020Phase 2 study in Diabetic Macular EdemaNCT04597918 · 99 enrolled · United States, Argentina, Canada and more
- Feb 3, 20213 phase 3 studiesNCT04740931, NCT04740905, NCT04777201
- Jan 25, 2022Phase 4 study in Diabetic Macular EdemaNCT05224102 · 218 enrolled · United States, India, Kenya and more
- Oct 4, 2022Phase 3 study in Neovascular Age-related Macular DegenerationNCT05569148 · 35 enrolled · United States
- Dec 11, 2023Phase 3 study in Choroidal Neovascularization Secondary to Pathologic MyopiaNCT06176352 · 280 enrolled · Australia, China, France and more
- Jan 24, 2025Phase 4 study in Neovascular Age-related Macular Degeneration (nAMD)NCT06795048 · 274 enrolled · United States, Australia, Canada and more
Ahead
- Jan 26, 2027Primary completion: phase 4 study in Diabetic Macular EdemaNCT05224102
TargetBeta
“A humanized bispecific antibody targeting both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2; Ang2; ANGPT2), that is used for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema”NCIt, by rule
“Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06795048Neovascular Age-related Macular Degeneration (nAMD) · United States, Australia, Canada and more | 4 | Active, not recruiting | Oct 16, 2026 | 274 |
| NCT06176352Choroidal Neovascularization Secondary to Pathologic Myopia · Australia, China, France and more | 3 | Completed | May 22, 2026 | 280 |
| NCT05569148Neovascular Age-related Macular Degeneration · United States | 3 | Completed | Nov 10, 2022 | 35 |
| NCT05224102Diabetic Macular Edema · United States, India, Kenya and more | 4 | Active, not recruiting | Jan 26, 2027 | 218 |
| NCT04777201Neovascular Age-related Macular Degeneration · United States, Argentina, Australia and more | 3 | Completed | Sep 3, 2024 | 1,036 |
| NCT04740931Macular Edema · United States, Argentina, Australia and more | 3 | Completed | Aug 9, 2022 | 729 |
| NCT04740905Macular Edema · United States, Argentina, Australia and more | 3 | Completed | Jul 6, 2022 | 553 |
| NCT04597918Diabetic Macular Edema · United States, Argentina, Canada and more | 2 | Completed | Dec 22, 2022 | 99 |
| NCT04432831Diabetic Macular Edema · United States, Argentina, Australia and more | 3 | Completed | Oct 11, 2023 | 1,479 |
| NCT03823300Wet Macular Degeneration · United States, Argentina, Australia and more | 3 | Completed | Oct 5, 2020 | 658 |
| NCT03823287Wet Macular Degeneration · United States, Canada, Germany and more | 3 | Completed | Oct 26, 2020 | 671 |
| NCT03622593Diabetic Macular Edema · United States, Argentina, Australia and more | 3 | Completed | Oct 19, 2020 | 951 |
| NCT03622580Diabetic Macular Edema · United States, Austria, Bulgaria and more | 3 | Completed | Oct 20, 2020 | 940 |
| NCT03038880Choroidal Neovascularization · United States | 2 | Completed | Jan 11, 2018 | 76 |
| NCT02699450Diabetic Macular Edema · United States | 2 | Completed | Sep 15, 2017 | 229 |
| NCT02484690Choroidal Neovascularization · United States | 2 | Completed | Sep 26, 2017 | 273 |
| NCT01941082Macular Degeneration · United States, United Kingdom | 1 | Completed | Feb 2015 | 24 |
How it is read
Names in the registry
- “Faricimab”, 15 entries
- “Faricimab PFS Configuration”, 1 entry
- “RO6867461”, 1 entry
Conditions, from the studies’ own filings
- Macular Edema, 9 studies
- Macular Degeneration, 3 studies
- Choroidal Neovascularization, 3 studies
- Wet Macular Degeneration, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.